Acute liver failure

This trial tests whether adding N-acetylcysteine (NAC) to standard care improves survival in adults with acute liver failure not caused by acetaminophen. Sixty-two patients will be randomly assigned to receive NAC or standard care alone. The study tracks survival at 28 days, hosp…

This early study tests whether using mesenchymal stem cells in a blood purification device is safe and can help adults with liver failure. Ten participants will receive the treatment alongside standard care. Researchers will track survival at 28 days and check for side effects. T…

This study tests a combined blood-filtering system (DPMAS and plasma exchange) in 25 adults with acute-on-chronic liver failure who are either waiting for a liver transplant or not eligible for one. The goal is to see if this artificial liver support can keep patients alive witho…

This study tests whether a standard volume of plasma exchange (blood filtering) works as well as a high volume in children aged 3 to 18 with acute liver failure. The goal is to see which approach helps more children survive without needing a liver transplant by day 21. Forty part…

This Phase 2 trial is testing an experimental drug called F573 in 97 people with acute liver failure or acute-on-chronic liver failure. Participants receive daily injections of F573 or a placebo for 7 days. The main goal is to check safety and side effects, while also looking at …

Researchers are testing whether a blood test that measures sugar chains on proteins can predict which liver transplant patients will lose their new organ or die within a year. The study enrolls 600 adults who are waiting for or have received a liver transplant. By analyzing blood…

This study is collecting information from 10,000 liver transplant patients across Europe to create a new, up-to-date reference for what good outcomes look like when using machine perfusion (a technique that keeps donated livers healthier before transplant). The goal is to help do…

This registry is tracking 3,000 critically ill patients who receive the CytoSorb blood-filtering device in real-world intensive care settings. The goal is to collect data on how the device is used and whether it relates to patient survival. It covers many conditions like sepsis, …